Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISION first-in-human phase 1/2 study of VV-14295 for geographic atrophy secondary to age-related macular degeneration
MOH_2025-11-24_015486Phase 2Not yet recruiting
- Sponsor
- Kriya Therapeutics, Inc.
- Start
- Jun 2025
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of KRIYA.825 in geographic atrophy (GA) and age-related macular degeneration (AMD) (3 arms), sponsored by Kriya Therapeutics, Inc. Primary endpoint: Safety and tolerability of VV-14295. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
KRIYA.825
03
Conditions
geographic atrophy (GA)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on MOH_2025-11-24_015486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-11-24_015486.